Rev Esp Quimioter 2023; 36(1):45-51

Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital

MARÍA JESÚS PÉREZ-GRANDA, PILAR CATALÁN, PATRICIA MUÑOZ, TERESA ALDÁMIZ, JUAN CAMILO BARRIOS, CARLOS RAMÍREZ, RITA GARCÍA-MARTÍNEZ, MARÍA VICTORIA VILLALBA, LUIS PUENTE, EMILIO BOUZA

Published: 22 November 2022

http://www.doi.org/10.37201/req/068.2022

Purpose. To determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital.
Methods. Point prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test.
Results. We included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coinfected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis.
Conclusion. CMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU.

Rev Esp Quimioter 2023; 36(1):45-51 [Full-text PDF]